ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
Dow Jones
38.852,27
0,46%
Euro vs US Dollar
1,07725
0,14%
Bitcoin
63.485,63
-0,80%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Evaxion Biotech AS (EVAX)

  7. Evaxion Biotech AS (EVAX) News

EVAX Evaxion Biotech AS

3,91
-0,04 (-1,01%)
Nach Börsenschluss
Zuletzt aktualisiert: 22:00:01
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Evaxion Biotech AS EVAX NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,04 -1,01% 3,91 22:00:01
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,99 3,79 4,16 3,91 3,95
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
06.5.202423:01EDGAR2Form F-1 - Registration statement for certain foreign..
17.4.202414:00GLOBEEvaxion Announces Phase 2 Clinical Trial Update: First..
02.4.202413:00GLOBEEvaxion and Undisclosed Collaborator Announce Encouraging..
27.3.202412:30GLOBEEvaxion Announces Business Update and Full Year 2023..
19.3.202412:30GLOBEEvaxion Hosts R&D Day and Unveils the Broad Potential of Its..
29.2.202413:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.2.202413:30GLOBEEvaxion to Host R&D Day on March 19, 2024, Highlighting its..
20.2.202413:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.2.202413:30GLOBEEvaxion Announces Successful Completion of the Initial..
07.2.202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.2.202414:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.2.202414:30GLOBEEvaxion Regains Compliance with Nasdaq Minimum Bid Price..
06.2.202414:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.2.202414:30GLOBEEvaxion Announces Closing of $15 Million Public Offering
05.2.202415:09EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05.2.202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
01.2.202415:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.2.202415:20GLOBEEvaxion Biotech Announces Pricing of $15 Million Public..
31.1.202423:10EDGAR2Form F-1/A - Registration statement for certain foreign..
31.1.202415:26EDGAR2Form F-1/A - Registration statement for certain foreign..
30.1.202421:16EDGAR2Form F-1/A - Registration statement for certain foreign..
26.1.202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24.1.202420:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24.1.202414:30GLOBEEvaxion to Develop Tailored Novel Cancer Vaccines Based upon..
22.1.202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.1.202422:30GLOBEEvaxion Announces Completion of ADS Ratio Change
12.1.202423:17EDGAR2Form F-1 - Registration statement for certain foreign..
12.1.202415:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.1.202414:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202414:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202414:30GLOBEEvaxion Announces Plan to Implement ADS Ratio Change
21.12.202322:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202322:30GLOBEEvaxion Biotech Announces Closing of Private Placement
19.12.202322:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19.12.202322:15GLOBEEvaxion Announces Business Update and Third Quarter 2023..
19.12.202315:25GLOBEEvaxion Biotech Announces Private Placement Financing
19.12.202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.12.202322:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.11.202314:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.11.202314:27GLOBEEvaxion to Unveil Potentially Groundbreaking AI-Immunology™..
17.11.202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15.11.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15.11.202314:00GLOBEEvaxion Presents Proof-of-Principle for Its Unique AI Model..
06.11.202316:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.11.202316:12GLOBEEvaxion Shares Latest EVX-01 Phase 2 Clinical Data in..
31.10.202316:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31.10.202316:14GLOBEEvaxion Announces Encouraging Initial Phase 2 Clinical Data..
26.10.202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26.10.202314:30GLOBENew and Exciting Clinical Data on Evaxion’s..

Kürzlich von Ihnen besucht

NASDAQ
EVAX
Evaxion Biotech AS
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten